ArriVent BioPharma, Inc. AVBP Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $62.1M+24.5% | $45.54M-38.7% | $112.67M-60.2% | $112.77M-62.2% | $49.87M-84.3% | ||
| $264.28M+109% | $267.28M+84.9% | $187.59M— | $122.92M— | $126.21M— | ||
| $22.32M+130% | $20.08M+147% | $20.95M+120% | $14.46M+46.9% | $9.71M-3.8% | ||
| $348.7M+87.7% | $332.9M+46.7% | $321.22M+9.9% | $250.15M-18.9% | $185.79M-43.3% | ||
| $370K+208% | $13K-91.6% | $49K-73.8% | $85K-61.2% | $120K-52.0% | ||
| $156K-11.4% | $190K+50.8% | $180K+42.9% | $479K+283% | $176K+63.0% | ||
| $349.3M+62.1% | $333.17M+21.2% | $326.56M+11.6% | $269.51M-12.7% | $215.5M-34.3% | ||
| $8.73M+100.0% | $5.93M+56.9% | $5.93M+27.7% | $4.06M+6.5% | $4.36M+6.5% | ||
| $16.17M+91.3% | $20M+50.0% | $15.57M+50.3% | $15.48M+90.3% | $8.45M+47.4% | ||
| $99K-28.3% | $14K-91.4% | $56K-64.3% | $98K-35.5% | $138K-6.1% | ||
| $25M+93.0% | $25.95M+50.2% | $21.56M+42.2% | $19.64M+62.3% | $12.95M+29.8% | ||
| $320K— | —— | —— | —— | —— | ||
| $25.32M+95.4% | $25.95M+50.1% | $21.56M+41.7% | $19.64M+61.0% | $12.95M+28.1% | ||
| $5K+25.0% | $4K+33.3% | $4K+33.3% | $4K+33.3% | $4K+33.3% | ||
| $772.21M+52.8% | $711.85M+43.5% | $673.88M+36.1% | $584M+18.3% | $505.28M+2.5% | ||
| -$447.96M-48.0% | -$404.64M-69.8% | -$369.1M-69.5% | -$334.12M-69.5% | -$302.72M-72.7% | ||
| -$270K-1,488% | $14K+107% | $206K— | -$18K— | -$17K— | ||
| $323.98M+60.0% | $307.22M+19.2% | $305M+9.9% | $249.87M-15.8% | $202.54M-36.3% | ||
| $349.3M+62.1% | $333.17M+21.2% | $326.56M+11.6% | $269.51M-12.7% | $215.5M-34.3% | ||
| $156K-11.4% | $190K+50.8% | $180K+42.9% | $479K+283% | $176K+63.0% | ||
| $370K+208% | $13K-91.6% | $49K-73.8% | $85K-61.2% | $120K-52.0% | ||
| $69K— | $69K— | —— | —— | —— | ||
| $370K+208% | $13K-91.6% | $49K-73.8% | $85K-61.2% | $120K-52.0% | ||
| $156K-11.4% | $190K+50.8% | $180K+42.9% | $479K+283% | $176K+63.0% | ||
| $264.28M+109% | $267.28M+84.9% | $187.59M— | $122.92M— | $126.21M— | ||
| $370K+208% | $13K-91.6% | $49K-73.8% | $85K-61.2% | $120K-52.0% | ||
| $156K-11.4% | $190K+50.8% | $180K+42.9% | $479K+283% | $176K+63.0% | ||
| $16.17M+91.3% | $20M+50.0% | $15.57M+50.3% | $15.48M+90.3% | $8.45M+47.4% | ||
| $16.17M+91.3% | $20M+50.0% | $15.57M+50.3% | $15.48M+90.3% | $8.45M+47.4% | ||
| $419K+204% | $14K-92.0% | $56K-73.7% | $98K-60.8% | $138K-51.6% | ||
| $5K+25.0% | $4K+33.3% | $4K+33.3% | $4K+33.3% | $4K+33.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can ArriVent BioPharma, Inc. cover its short-term obligations?
- Its current ratio is 13.95 — current assets exceed current liabilities.
- Where does ArriVent BioPharma, Inc.'s balance sheet data come from?
- Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.